Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has initiated a Phase 1/2 trial for ZN-c3, an oral WEE1 inhibitor, in combination with gemcitabine for treating relapsed or refractory osteosarcoma. The trial aims to evaluate clinical safety and efficacy, with initial results expected in the second half of 2022. Zentalis has received orphan drug and rare pediatric disease designations from the FDA for this indication, potentially leading to a priority voucher upon approval. Osteosarcoma, primarily affecting younger patients, has a poor prognosis, highlighting the urgent need for effective therapies.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced the acceptance of six abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress, taking place virtually from September 16-21, 2021. Highlights include studies on ZN-c3, a WEE1 inhibitor, and ZN-c5, an oral selective estrogen receptor degrader, targeting advanced cancers. The posters will be accessible on the Congress platform starting September 16 at 8:30 a.m. CEST and will also appear on Zentalis' website.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced participation in two virtual investor conferences. The Morgan Stanley Global Healthcare Conference is on September 10, 2021, at 2:45 p.m. EDT, featuring a live fireside chat with CEO Anthony Sun. The H.C. Wainwright Global Life Sciences Conference follows on September 13, 2021, at 7:00 a.m. EDT, presented on demand. Webcasts will be available on the company’s website, showcasing Zentalis's focus on developing small molecule therapeutics for cancer.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the publication of its WEE1 inhibitor candidate, ZN-c3, in the Journal of Medicinal Chemistry. This selective WEE1 inhibitor aims to enhance cancer treatment efficacy by targeting the cell cycle regulator WEE1. ZN-c3 is under evaluation in multiple trials, including potential accelerated approval routes for uterine serous carcinoma. The company believes ZN-c3's profile may represent a best-in-class oncology treatment, following promising clinical results reported in June.

Zentalis Pharmaceuticals (ZNTL) reported promising new data for ZN-c3 and ZN-c5, highlighting their potential as best-in-class cancer therapies. The company successfully dosed the first patient in a Phase 2 trial for ZN-c3 targeting uterine serous carcinoma (USC). Additionally, Zentalis raised approximately $173 million in a public offering to support future milestones. The second quarter of 2021 saw a net loss of $55.1 million, driven by increased R&D expenses. As of June 30, 2021, Zentalis held $250.9 million in cash, which is expected to fund operations well into Q3 2023.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The event will be accessible via a live webcast on the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer, with a pipeline including candidates like ZN-c3 and ZN-c5 targeting various tumors. The company operates in New York and San Diego.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of the first patient in a Phase 2 trial for ZN-c3, an oral WEE1 inhibitor, targeting recurrent uterine serous carcinoma (USC). The FDA indicated that ZN-c3 may pursue an accelerated approval pathway based on the trial's design. This Phase 2 trial aims to evaluate the drug's clinical activity, safety, and pharmacokinetics. USC has a poor prognosis, with survival rates of only 30-50%, highlighting the urgent need for effective therapies. ZN-c3 is positioned as a potentially first-in-class treatment, which could redefine USC care.

Zentera Therapeutics has successfully completed a $75 million Series B financing, led by OrbiMed Advisors Asia and Tybourne Capital Management. The funds will support the clinical development of three oncology candidates from Zentalis Pharmaceuticals (Nasdaq: ZNTL) in China, including WEE1 inhibitor ZN-c3, oral SERD ZN-c5, and BCL-2 inhibitor ZN-d5. Zentera has received four Clinical Trial Applications approved in China and aims to advance its pipeline further. The leadership team expresses confidence in becoming a leading biopharmaceutical company focused on delivering innovative cancer therapies.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) has completed an underwritten public offering, raising approximately $172.9 million by selling 3,565,000 shares at $48.50 each, including 465,000 shares from underwriters' options. This funding will support Zentalis' development of oncology therapeutics targeting cancer pathways. The offering utilized an effective shelf registration statement filed with the SEC on May 4, 2021, with Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities as joint managers.